Santhera's FJORD Phase IIb Study Demonstrates Efficacy of JP-1730for the Treatment of Dyskinesia in Parkinson's Disease

02-Jul-2009 - Switzerland

Seamlessly Digitize Your Quality Management

Image integrity checker software - authenticate your images for publication

Maximum binding capacity in ion exchange chromatography

Santhera Pharmaceuticals announced positive data from its Phase IIb study (FJORD). The key finding of the trial is that JP-1730/ fipamezole reduces levodopa-induced dyskinesia in Parkinson's patients. This beneficial effect was not associated with a worsening of Parkinsonian features of the disease. The data additionally suggest that JP-1730/fipamezole reduces "off time" and improves cognitive function as well as clinical global impression in dyskinesia. The compound was found to be safe and well tolerated.

The FJORD study was a double-blind, randomized, placebo-controlled, multiple dose-escalating study of the safety, tolerability and efficacy of JP-1730/fipamezole in the treatment of levodopa-induced dyskinesia in Parkinson's Disease patients. The study investigated the efficacy of three doses (30, 60 and 90 mg) compared to placebo over a treatment period of 28 days in 179 patients enrolled at a total of 33 sites in the US (26) and India (7). The primary study endpoint was the suppression of levodopa-induced dyskinesia as measured by the Levodopa Induced Dyskinesia Scale (LIDS). The LIDS is a modified version of the Abnormal Involuntary Movement Scale, an evaluation tool widely used in clinical research.

https://www.bionity.com/en/news/102772/santhera-s-fjord-phase-iib-study-demonstrates-efficacy-of-jp-1730for-the-treatment-of-dyskinesia-in-parkinson-s-disease.html